Neurogenic Bladder: Recurrent Urinary Tract Infections—Beyond Antibiotics
- 81 Downloads
Purpose of Review
Our goal was to identify evidenced-based strategies to prevent and treat patients with neurogenic bladder who suffer from recurrent urinary tract infections. We focused on therapy beyond standard antibiotics to address a multitude of factors implicated in these complex infections.
Anatomic and functional components specific to neurogenic bladder contribute to the risk of infection and require close clinical monitoring. The host-pathogen interaction is one that allows for colonization of bacteria in the bladder. We recognize that bacteriuria in the neurogenic bladder population does not equate with infection. Local antibiotic treatment and oral supplements are often not adequate to eliminate infection nor prevent recurrent infection due to biofilms. However, novel medical therapies, such as photodynamic therapy, bacterial interference, and infrared laser therapy to augment local immune cells, are promising options to prevent and treat symptomatic infection.
A combination approach including management of anatomic and functional factors with medical intervention can significantly improve frequency of urinary infection. Further study of non-antibiotic therapeutic strategies is much needed as we recognize the complexity of the urinary biomes and the limitations of antibiotic therapies.
KeywordsNeurogenic bladder Neurogenic UTI Recurrent urinary tract infection Catheter-associated UTI
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.Bergamin PA, Kiosoglous AJ. Surgical management of recurrent urinary tract infections: a review. Translational Androl Urol. 2017;6(Suppl 2):S153–62.Google Scholar
- 14.Fouts DE, Pieper R, Szpakowski S, Pohl H, Knoblach S, Suh MJ, et al. Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J Transl Med. 2012;10:174.PubMedPubMedCentralGoogle Scholar
- 15.Levy J, Breton FL, Jousse M, Haddad R, Verollet D, Guinet-Lacoste A, et al. Bacterial ecology and antibiotic resistance in patients with neurogenic overactive bladder treated by botulinum toxin injections. Ann Phys Rehabil Med. 2013;56:e233.Google Scholar
- 18.Hooton T, Bradley S, Cardenas D, Colgan R, Geerlings S, Rice J, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625–63.PubMedGoogle Scholar
- 22.Forster C, Haslam D, Jackson E, Goldstein S. Utility of a routine urinalysis in children who require clean intermittent catheterization. J Pediatr Urol. 2017;13(5):488. https://doi.org/10.1016/j.jpurol.2017.01.016.
- 23.Schlager T, Anderson S, Trudell J, Hendley J. Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization. J Urol. 1999;161(1):372.Google Scholar
- 26.Akil I, Ozen C, Cengiz B. Do patient with neurogenic bladder treated with clean intermittent catheterization need antibacterial prophylaxis? Turkish J Med Sci. 2016;46(4):1151–4.Google Scholar
- 27.Niël-Weise BS, van den Broek PJ, da Silva EMK, Silva LA. Urinary catheter policies for long-term bladder drainage. Cochrane Database Syst Rev. 2012;8 https://doi.org/10.1002/14651858.CD004201.pub3.
- 29.Christmas T, Rode J. Characteristics of mast cells in normal bladder, bacterial cystitis and interstitial cystitis. BJU Int. 1991;68(5):473–8.Google Scholar
- 35.Esclarin DRA, Garcia LE, Herruzo CR. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol. 2000;164(4):1285–9.Google Scholar
- 38.Stamm W. Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention. Am J Med. 1991;99:655–715.Google Scholar
- 42.Rhone C, Breiter Y, Benson L, Petri H, Thompson P, Murphy C. The impact of two-person indwelling urinary catheter insertion in the emergency department using technical and socioadaptive interventions. J Clin Outcomes Manag. 2017;24(10). Retrived from: https://www.mdedge.com/jcomjournal/article/149684/emergency-medicine/impact-two-person-indwellingurinary-catheter/page/0/1
- 43.American Nurses Association. Streamlined evidence-based RN tool: catheter associated urinary tract infection (CAUTI) prevention. 2014; https://www.nursingworld.org/~4aede8/globalassets/practiceandpolicy/innovation%2D%2Devidence/clinical-practice-material/cauti-prevention-tool/anacautipreventiontool-final-19dec2014.pdf.
- 44.Moore KN, Fader M, Getliffe K. Long-term bladder management by intermittent catheterisation in adults and children. Cochrane Database Sys Rev. 2007; https://doi.org/10.1002/14651858.CD006008.pub2.
- 45.De Ridder DJ, Everaert K, Fernandez LG, et al. Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: a prospective randomised parallel comparative trial. Eur Urol. 2005;48:991–5.PubMedGoogle Scholar
- 47.Kanaheswari Y, Kavitha R, Rizal AM. Urinary tract infection and bacteriuria in children performing clean intermittent catheterization with reused catheters. Spinal Cord. 2014;53:209–12.Google Scholar
- 49.Bermingham SL, Hodgkinson S, Wright S, Hayter E, Spinks J, Pellowe C. Intermittent self catheterisation with hydrophilic, gel reservoir, and non-coated catheters: a systematic review and cost effectiveness analysis. BMJ. 2013;346. https://doi.org/10.1136/bmj.e8639.
- 53.National Clinical Guideline Centre (NICE). Infection: prevention and control of healthcare-associated infections in primary and community care: partial update of NICE clinical guideline 2 (UK). 2012; 10 (139). https://www.ncbi.nlm.nih.gov/books/NBK115272/.
- 54.Cicione A, Cantiello F, Ucciero G, Salonia A, Torella M, de Sio M, et al. Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: results from a multicentre survey. Can Urol Assoc J. 2014;8(9–10):E721–7. https://doi.org/10.5489/cuaj.1989.CrossRefPubMedPubMedCentralGoogle Scholar
- 58.Cottenden A, Bliss DZ, Buckley B, Fader M, Getliffe K, Paterson J, et al. Management using continence products. International Continence Society. 2017;6:1519–642.Google Scholar
- 60.Johnson JR, Kuskowski MA, Wilt TJ. Systematic review: antimicrobial urinary catheters to prevent catheter-associated urinary tract infection in hospitalized patients. Ann Intern Med. 2006;144(2):166–26.Google Scholar
- 64.Pickard R, Lam T, Maclennan G, Starr K, Kilonzo M, McPherson G, et al. Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation: Multicentre randomised controlled trial and economic evaluation of antimicrobial- and antiseptic-impregnated urethral catheters (the CATHETER trial). Health Technol Assess. 2012;16(47):1–197.PubMedPubMedCentralGoogle Scholar
- 66.Schumm K, Lam TB. Types of urethral catheters for management of short-term voiding problems in hospitalised adults. Cochrane Database Syst Rev. 2008; 2. Art. No.: CD004013. https://doi.org/10.1002/14651858.CD004013.pub3.
- 67.Jahn P, Preuss M, Kernig A, Langer G, Seifert-Huehmer A. Types of indwelling urinary catheters for long-term bladder drainage in adults. Cochrane Database Syst Rev. 2007; 3. Art. No.: CD004997. https://doi.org/10.1002/14651858.CD004997.pub2.
- 69.Mandakhalikar K, Chua R, Tambyah P. New technologies for prevention of catheter associated urinary tract infection. Curr Treatment Options Infect Dis. 2016;8(1):24–41.Google Scholar
- 73.Toh SL, Boswell-Ruys CL, Lee BSB, Simpson JM, Clezy KR. Probiotics for preventing urinary tract infection in people with neuropathic bladder. Cochrane Database Syst Rev. 2017; 9. Art. No.: CD010723. https://doi.org/10.1002/14651858.CD010723.pub2.
- 74.•• Huang YY, Wintner A, Seed PC, Brauns T, Gelfand JA, Hamblin MR. Antimicrobial photodynamic therapy mediated by methylene blue and potassium iodide to treat urinary tract infection in a female rat model. Sci Rep. 2018;8(1):7257. Novel approach to treating drug resistant CAUTI PubMedPubMedCentralGoogle Scholar
- 75.• He Y, Huang YY, Xi L, Gelfand JA, Hamblin MR. Tetracyclines function as dual-action light-activated antibiotics. PloS one. 2018;13(5):e0196485. Tetracycline antibiotics, which may be photoactivated, help prevent regrowth of gram positive and gram negative bacteria in culture media. PubMedPubMedCentralGoogle Scholar
- 76.•• Wang Y, Wu X, Chen J, Amin R, Lu M, Bhayana B, et al. Antimicrobial blue light inactivation of gram-negative pathogens in biofilms: in vitro and in vivo studies. J Infect Dis. 2016;213(9):1380–7. Blue light can inactive gram negative bacilli and act as antimicrobial agent specifically targeting biofilms PubMedPubMedCentralGoogle Scholar
- 81.Gelfand JA, Kashiwagi S, Brauns T, Martin B, Kimizuka Y, Botvinick E, Elkins K, Thomas L, Loscascio J, Parry B, Kelly KM, Poznansky MC. A pilot clinical trial of a near infrared laser vaccine adjuvant: safety, tolerability, and cutaneous immune cell trafficking. FASEB J. 2018 (accepted).Google Scholar
- 82.Kimizuka Y, Locascio J, Shigeta A, Shibata M, Morse K, Reeves P, Suematsu M, Gelfand J, Brauns T, Poznansky M, Tsukada K, Kashiwagi S. Brief exposures of skin to near-infrared light modulates mast cell function and augments the immune response. J of Immunology. 2018 (accepted).Google Scholar
- 85.Howell AB, Botto H, Combescure C, Blanc-Potard AB, Gausa L, Matsumoto T, et al. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect Dis. 2010 Apr 14;10:94.PubMedPubMedCentralGoogle Scholar
- 87.Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012; Issue 10. Art. No.: CD001321. https://doi.org/10.1002/14651858.CD001321.pub5.
- 88.Beerepoot M, Geerlings S. Non-antibiotic prophylaxis for urinary tract infections. Young LS, Svanborg C, eds. Pathogens. 2016;5(2):36.Google Scholar
- 89.Asma B, Vicky L, Stephanie D, Yves D, Amy H, Sylvie D. Standardised high dose versus low dose cranberry proanthocyanidin extracts for the prevention of recurrent urinary tract infection in healthy women [PACCANN]: a double blind randomised controlled trial protocol. BMC Urol. 2018;18(1):29.PubMedPubMedCentralGoogle Scholar
- 90.Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev. 2015 Dec 23;12:CD008772.Google Scholar
- 101.Habibi M, Asadi Karam MR, Shokrgozar MA, Oloomi M, Jafari A, Bouzari S. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis. Mol Immunol. 2015 Apr;64(2):285–94.PubMedGoogle Scholar